Related Experiment Videos
APP processing and the APP-KPI domain involvement in the amyloid cascade
M Menéndez-González1, P Pérez-Pinera, M Martínez-Rivera
1Neurology Department, Hospital Universitario Central de Asturias, Oviedo, Spain. manuelmenendez@gmail.com
Neuro-Degenerative Diseases
|August 16, 2006
Summary
The Kunitz protease inhibitor (KPI) domain in amyloid precursor protein (APP) is elevated in Alzheimer's disease (AD) brains, contributing to amyloid beta deposition and disease pathogenesis.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Alternative splicing of amyloid precursor protein (APP) mRNA generates isoforms containing a Kunitz protease inhibitor (KPI) domain.
- KPI is a significant serine protease inhibitor.
- Elevated levels of KPI(+)APP protein and mRNA are observed in Alzheimer's disease (AD) brains, correlating with increased amyloid beta deposition.
Purpose of the Study:
- To review the role of KPI(+)APP in Alzheimer's disease pathogenesis.
- To explore APP processing and the molecular activity of KPI.
- To examine the physiological and pathological roles of KPI.
Main Methods:
- Literature review focusing on APP processing.
- Analysis of KPI's molecular activity and its roles.
- Investigation of KPI's involvement in the amyloid cascade via specific pathways.
Main Results:
- Accumulating evidence highlights multiple points in the amyloid cascade where KPI(+)APP is implicated.
- The KPI domain holds a significant position in AD pathogenesis.
- KPI(+)APP influences the amyloid cascade through interactions with nerve growth factor, LRP, TACE, and Notch1.
Conclusions:
- The KPI domain is a key player in the pathogenesis of Alzheimer's disease.
- Understanding KPI's role in APP processing and the amyloid cascade is crucial for AD research.
- Further investigation into KPI's interactions may reveal novel therapeutic targets for AD.